A letter about FDA oncology consolidation reopens debate among cancer groups; FDA asks groups not to send letters, invites discussion.
Also in this 12-page issue: GM Cancer Research Foundation awards annual prizes to four scientists.
Age-adjusted cancer incidence and mortality down slightly, annual report finds.
Bills in House, Senate, would give FDA authority over tobacco products.
Surgeon General’s report adds to list of smoking-related cancers, other diseases.
ASCO honors physicians for clinical trials participation.
President’s Cancer Panel urges comprehensive health care reform, provision of services for cancer survivors.
Funding opportunities listed.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- GRAIL presses on with Galleri test despite missed primary endpoint in pivotal study
Where GRAIL sees signals of benefit in the subgroups, screening experts see signs of overdiagnosis - Vinay Prasad, oncologist and Twitter star, locked in debate over precision medicine
- Lawsuits brought against Tempus AI raise more questions than answers about DNA privacy in the AI era
- GRAIL’s Megan Hall: “I think we can be confident that there is clinical benefit to implementing this technology. And I think that’s really hard to argue with.”
Mainstream epidemiologists beg to differ - NCI’s Philip Castle on NHS-Galleri results: “I’m sorry that it didn’t work, but it keeps the national conversation going.”
Castle is “disappointed” by Galleri results but not discouraged by implications for MCDs
